Glioblastoma is the most common and aggressive type of primary brain tumor, with an average survival rate of 15 months, ...

Glioblastoma is the most common – and the most malignant – primary brain tumour in adults. It's aggressive and incurable.

In a small but important Phase 1 study, MTX110 is outperforming historic norms of progression free and overall survival ...

A recent study has revealed that chloride flow through channels on the surface of tumor cell lines plays a crucial role in ...

The agent is currently being evaluated in a phase 1a study, and a phase 1b/2a study will continue to assess LP-184’s safety ...

Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and ...

Glioblastoma Treatment Drugs MarketThe glioblastoma treatment drugs market is poised for substantial growth, with a projected valuation of approximately USD 756.1 million in 2023. The market is ...

Chloride ion flows that enter the cells play an important role in the duplication of glioblastoma cells, a highly aggressive ...

Shilpa Medicare's drug is presently undergoing a Phase 1A clinical trial to test its safety and how well it is tolerated in ...

For patients with glioblastoma imaged daily with magnetic resonance imaging (MRI)-linear accelerator (linac) throughout the ...

Discover a groundbreaking treatment strategy for glioblastoma that enhances traditional therapies. Promising results could ...

Biodexa Pharmaceuticals PLC (NASDAQ:BDRX) stock is trading lower on Thursday. The company released patient updates on ...